EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Warren, Richard B. [2 ]
Silverberg, Jonathan I. [3 ]
Guttman-Yassky, Emma [4 ]
Thaci, Diamant [5 ]
Irvine, Alan D. [6 ]
Gold, Linda Stein [7 ]
Blauvelt, Andrew [8 ]
Simpson, Eric L. [9 ]
Chu, Chia-Yu [10 ,11 ]
Liu, Zhuqing T. [12 ]
Lima, Renata Gontijo [12 ]
Pillai, Sreekumar [12 ]
Gil, Esther Garcia [13 ]
Seneschal, Julien [14 ,15 ]
机构：
[1] LMU Dept Dermatol & Allergol, Munich, Germany
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester Nihr Biomed Res Ctr, Manchester, Lancs, England
[3] George Washington Univ, Dept Dermatol, Sch Med, Washington, DC USA
[4] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[7] Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA
[8] Oregon Med Res Ctr, Portland, OR USA
[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[10] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[11] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[12] Eli Lilly & Co, Indianapolis, IN USA
[13] Almirall SA, Barcelona, Spain
[14] Univ Bordeaux, Dept Dermatol, Bordeaux, France
[15] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P10.9
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Gil, Esther Garcia
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
  • [22] Efficacy and safety of dupilumab in adult patients with atopic dermatitis and an inadequate response, intolerance, or contraindication to cyclosporine: pooled analysis of two 16-week phase 3 trials
    De Bruin-Weller, M. S.
    Bieber, T.
    Kawashima, M.
    Schmitt, J.
    Sun, X.
    Gadkari, A.
    Eckert, L.
    Graham, N. M.
    Pirozzi, G.
    Akinlade, B.
    Ardeleanu, M.
    Hultsch, T.
    ALLERGY, 2017, 72 : 46 - 47
  • [23] The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
    Soung, Jennifer
    Laquer, Vivian
    Merola, Joseph F.
    Moore, Angela
    Elmaraghy, Hany
    Hu, Chaoran
    Piruzeli, Maria Lucia Buziqui
    Pierce, Evangeline
    Gil, Esther Garcia
    Jarell, Abel D.
    DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2181 - 2193
  • [24] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
    Silverberg, Jonathan I.
    Thaci, Diamant
    Seneschal, Julien
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Guttman-Yassky, Emma
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98
  • [25] Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
    Simpson, Eric L.
    Pink, Andrew E.
    Blauvelt, Andrew
    Gooderham, Melinda
    Armstrong, April W.
    Worm, Margitta
    Katoh, Norito
    Peris, Ketty
    Puig, Luis
    Barbarot, Sebastien
    Mark, Thomas
    Steffensen, Louise Abildgaard
    Tindberg, Ann-Marie
    Wollenberg, Andreas
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (06) : 939 - 952
  • [26] Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
    Eric L. Simpson
    Andrew E. Pink
    Andrew Blauvelt
    Melinda Gooderham
    April W. Armstrong
    Margitta Worm
    Norito Katoh
    Ketty Peris
    Luis Puig
    Sébastien Barbarot
    Thomas Mark
    Louise Abildgaard Steffensen
    Ann-Marie Tindberg
    Andreas Wollenberg
    American Journal of Clinical Dermatology, 2023, 24 : 939 - 952
  • [27] Dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid asthma requiring treatment: Analysis from two pooled phase 3 trials (liberty ad solo 1&2)
    Beck, L. A.
    Deleuran, M.
    Guttman-Yassky, E.
    Kingo, K.
    Chen, Z.
    Graham, N. M. H.
    Pirozzi, G.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    ALLERGY, 2018, 73 : 76 - 77
  • [28] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate to severe atopic dermatitis: Results from three phase 3 trials
    Chovatiya, Raj
    Schuttelaar, Marie-Louise
    Calimlim, Brian
    Liu, Yingyi
    Takemoto, Shunya
    Staender, Sonja
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1017 - 1018
  • [29] Lebrikizumab does not impact vaccine-induced immune responses: results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis
    Soung, Jennifer
    Laquer, Vivian
    Merola, Joseph F.
    Forman, Seth
    Elmaraghy, Hany
    Meskimen, Eric
    Hu, Chaoran
    Natalie, Chitra R.
    Pierce, Evangeline
    Torisu-Itakura, Hitoe
    Gil, Esther Garcia
    Jarell, Abel D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II4 - II4
  • [30] Lebrikizumab does not impact vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis
    Soung, J.
    Laquer, V.
    Merola, J. F.
    Forman, S.
    Elmaraghy, H.
    Meskimen, E.
    Hu, C.
    Natalie, C.
    Pierce, E.
    Torisu-Itakura, H.
    Gil, E.
    Jarell, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (09) : B15 - B15
12345